Patent · US Expired

Fusion proteins of humanized g250 specific antibodies and uses thereof

US7714113B2 · kind B2 · utility

2Cited by

1References

9Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Christoph Renner · Partenstein, DE
Andrew Scott · Melbourne, AU

Key dates

Filing date	Feb 12, 2003
Grant date	May 11, 2010
Priority date	—
Expiry date	Feb 12, 2023

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.